{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:07:20Z","timestamp":1791511640088,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.japh.2023.10.037","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T23:57:44Z","timestamp":1699315064000},"page":"204-211.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7123-7716","authenticated-orcid":false,"given":"Jessica W.","family":"Skelley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7539-5195","authenticated-orcid":false,"given":"Katelyn","family":"Swearengin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriane L.","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey H.","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.japh.2023.10.037_bib1","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.japh.2023.10.037_bib2","author":"Joffe"},{"issue":"10","key":"10.1016\/j.japh.2023.10.037_bib3","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/dom.14110","article-title":"The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists","volume":"22","author":"Urva","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.japh.2023.10.037_bib4","unstructured":"Mounjaro. Injection [package insert]. Indianapolis, IN: Eli Lilly and Company. (Tirzepatide). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf. 2022. Accessed May 11, 2023."},{"issue":"1","key":"10.1016\/j.japh.2023.10.037_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12933-021-01412-5","article-title":"The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect","volume":"20","author":"Fisman","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.japh.2023.10.037_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1004044","article-title":"Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity","volume":"13","author":"Gallwitz","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.japh.2023.10.037_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jcph.443","article-title":"Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel","volume":"55","author":"Kapitza","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.japh.2023.10.037_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.15406\/japlr.2019.08.00311","article-title":"Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists","volume":"8","author":"Maideen","year":"2019","journal-title":"JAPLR"},{"issue":"6","key":"10.1016\/j.japh.2023.10.037_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.japh.2023.10.037_bib10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s40262-017-0531-7","article-title":"No dose adjustment is recommended for digoxin, warfarin, atorvastatin or a combination oral contraceptive when coadministered with dulaglutide","volume":"56","author":"de la Pe\u00f1a","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.japh.2023.10.037_bib12","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40262-020-00976-x","article-title":"Effect of oral semaglutide on the pharmacokinetics of levonorgestrel and ethinylestradiol in healthy postmenopausal women and furosemide and rosuvastatin in healthy subjects","volume":"60","author":"Jordy","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.japh.2023.10.037_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6904-12-8","article-title":"Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial","volume":"12","author":"Kothare","year":"2012","journal-title":"BMC Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.japh.2023.10.037_bib14","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1177\/0091270010389471","article-title":"Treatment with liraglutide\u2014a once-daily GLP-1 analog\u2014does not reduce the bioavailability of ethinyl estradiol\/levonorgestrel taken as an oral combination contraceptive drug","volume":"51","author":"Jacobsen","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.japh.2023.10.037_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2337\/db13-1764","article-title":"Give the receptor a brake: slowing gastric emptying by GLP-1","volume":"63","author":"Tong","year":"2014","journal-title":"Am Diabetes Assoc"},{"key":"10.1016\/j.japh.2023.10.037_bib20","author":"John"},{"key":"10.1016\/j.japh.2023.10.037_bib21","author":"Miller"},{"issue":"1","key":"10.1016\/j.japh.2023.10.037_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective","volume":"25","author":"De Block","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.japh.2023.10.037_bib23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.diabet.2017.05.009","article-title":"Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy","volume":"43","author":"Nakatani","year":"2017","journal-title":"Diabetes Metab"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123003709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123003709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:53:05Z","timestamp":1761544385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123003709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1544319123003709"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.10.037","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.10.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}